Health & Fitness
Thu, March 24, 2011Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sun, March 20, 2011Fri, March 18, 2011Thu, March 17, 2011Wed, March 16, 2011Tue, March 15, 2011Mon, March 14, 2011Sun, March 13, 2011Sat, March 12, 2011Fri, March 11, 2011Thu, March 10, 2011Wed, March 9, 2011Tue, March 8, 2011Mon, March 7, 2011Sat, March 5, 2011Fri, March 4, 2011Thu, March 3, 2011Human Genome Sciences Appoints George Morrow to its Board of Directors
//health-fitness.news-articles.net/content/2011/ .. nts-george-morrow-to-its-board-of-directors.html
Published in Health and Fitness on Monday, March 14th 2011 at 3:40 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
ROCKVILLE, Md.--([ BUSINESS WIRE ])--Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that George J. Morrow, former Executive Vice President, Global Commercial Operations, Amgen Inc., has been appointed to the HGS Board of Directors.
"George Morrow has more than 30 years of leadership experience in worldwide commercial operations and we are honored to have him join our Board of Directors"
aGeorge Morrow has more than 30 years of leadership experience in worldwide commercial operations and we are honored to have him join our Board of Directors,a said H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences. aGeorge has a remarkable record of success at some of the worlda™s leading biopharmaceutical firms. We look forward to benefiting from his insight and experience at this critical time in our companya™s history, as we complete our transition to a fully commercialized company and bring our first product to the marketplace.a
Mr. Morrow served as Executive Vice President, Global Commercial Operations of Amgen Inc. from April 2003 until January 31, 2011. In that role, he was responsible for leading all commercial activities in over 50 countries and helped launch multiple products into competitive markets. From 2001 to 2003, he served as Amgena™s Executive Vice President, Worldwide Sales and Marketing. Before joining Amgen, Morrow had over 20 years of commercial experience at Merck and GlaxoWellcome. He served as President and Chief Executive Officer of GlaxoWellcome Inc. and as Managing Director of GlaxoWellcome U.K., both subsidiaries of GlaxoSmithKline plc. Prior to that, he was Group Vice President for Commercial Operations, Glaxo Inc. from 1993-1996.
Mr. Morrow holds a B.S. in chemistry from Southampton College, Long Island University; an M.S. in biochemistry from Bryn Mawr College; and an M.B.A. from Duke Universitya™s Fuqua School of Business. He is a member of the Duke University Fuqua School of Business Advisory Board and Medical Center Board of Visitors. He is also a member of the Board of Directors of Align Technology, a global medical device company. Mr. Morrow has served previously on boards for GlaxoWellcome Inc. and Johns Hopkins School of Public Health.
ABOUT HUMAN GENOME SCIENCES
Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.
For more information about HGS, please visit the Companya™s web site at [ www.hgsi.com ]. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to [ medinfo@hgsi.com ] or by calling HGS at (877) 822-8472. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.
SAFE HARBOR STATEMENT
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciencesa™ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciencesa™ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciencesa™ ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciencesa™ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Companya™s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of todaya™s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.